

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINOPHARM GROUP CO. LTD.* **國藥控股股份有限公司**

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)

CHANGE OF JOINT COMPANY SECRETARY

The board of directors (the “**Board**”) of Sinopharm Group Co. Ltd. (the “**Company**”) announces that on 22 March 2012, the Board resolved that Mr. Wu Aimin resigned from his positions as the joint company secretary of the Company and the secretary to the Board, and Mr. Ma Wanjun (“**Mr. Ma**”) was appointed as the new joint company secretary of the Company and the secretary to the Board, with effect from 22 March 2012.

The Board also announces that, the Company has applied for, and The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) has granted a waiver to the Company from strict compliance with the requirements under Rule 3.28 of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (the “**Listing Rules**”) for a period of three years from the date of appointment of Mr. Ma in respect of the appointment of Mr. Ma as the joint company secretary of the Company, on the condition that Mr. Ma will be assisted by Dr. Liu Wei (“**Dr. Liu**”) to acquire the relevant experience within the meaning of Rule 3.28 of the Listing Rules and to discharge his duties as the joint company secretary of the Company. Dr. Liu has PRC lawyer qualification and is qualified to practice as a solicitor in Hong Kong and England. Dr. Liu has served as the joint company secretary of the Company since 24 August 2011.

The Board would like to take this opportunity to express its gratitude to Mr. Wu Aimin for his contribution to the Company during his tenure as the joint company secretary of the Company and the secretary to the Board, and to express its warm welcome to Mr. Ma for his appointment as the new joint company secretary of the Company and the secretary to the Board.

BIOGRAPHICAL DETAILS

Mr. Ma Wanjun, aged 43, acted as a vice president of the Company since September 2010. He obtained a bachelor of science degree in chemistry from Nankai University in July 1991 and an EMBA from China Europe International Business School in September 2006. He is a senior pharmacist. He was a business officer and manager in purchase and supply station of China National Pharmaceutical (Group) Tianjin Corporation from July 1991 to November 1999, and deputy general manager of general affairs of China National Pharmaceutical (Group) Tianjin Corporation from December 1999 to May 2003. Since he joined the Company in May 2003, he has held various positions including the general manager and deputy general manager of department of pharmaceutical business of Sinopharm Holding Tianjin Co., Ltd., the general manager and deputy general manager of operation centre of Sinopharm Holding Distribution Co., Ltd., and director of Sinopharm Holding Shenyang Co., Ltd., Sinopharm Holding Suzhou Co., Ltd., Sinopharm Holding Changzhou Co., Ltd., Sinopharm Group Shanxi Co. Ltd and Shanghai Bionuo Medicines Company. He is currently the chairman of Sinopharm Holding Henan Co., Ltd., Guangdong Dong Fang Uptodate & Special Medicines Co., Ltd. and Sinopharm Health Industry (Shanghai) Co., Ltd, respectively, and also a director of Sinopharm Group Accord Pharmaceutical Co., Ltd., Sinopharm Le Ren Tang Pharmaceutical Co., Ltd., Sinopharm Group Pharmaceutical Co. Ltd. and Yu Jia Medicine Service Co. Ltd., respectively.

By order of the Board
Sinopharm Group Co. Ltd.
She Lulin
Chairman

Shanghai, the PRC

22 March 2012

As at the date of this announcement, the executive director of the Company is Mr. Wei Yulin; the non-executive directors of the Company are Mr. She Lulin, Mr. Wang Qunbin, Mr. Chen Wenhao, Mr. Zhou Bin, Mr. Chen Qiyu, Mr. Deng Jindong, Mr. Fan Banghan and Mr. Liu Hailiang; and the independent non-executive directors of the Company are Mr. Wang Fanghua, Mr. Tao Wuping, Mr. Xie Rong and Mr. Zhou Bajun.

* *The Company is registered as a non-Hong Kong company under Part XI of the Companies Ordinance (Chapter 32 of the Laws of Hong Kong) under its Chinese name and the English name "Sinopharm Group Co. Ltd."*